NEW YORK (TheStreet) -- Shares of Pfizer (PFE) - Get Pfizer Inc. Report closed down by 0.15% to $33.67 on Monday, while European regulators lifted a warning on the company's smoking suppressant drug Champix - known as Chantix in the U.S. - which used to state the drug could increase a person's risk of neuropsychiatric side effects, Fox News reports.
Champix is an approved drug credited with helping people quit smoking. A clinical study recently disproved reports that the drug is linked to agitation, aggression, panic, anxiety, depression and suicidal thoughts, Fox says.
The European Medicines Agency had labeled Champix with a "black triangle" warning, which will now be removed from its packaging after the results of the study, conducted in April, were revealed.
Pfizer is still awaiting approval from the Food and Drug Administration to remove the warning label in the U.S., Fox notes.
New York City-based Pfizer is a research-based global biopharmaceutical company, engaged in discovering, developing and manufacturing healthcare products.
Separately, TheStreet Ratings rated Pfizer as a "hold" with a score of C+.
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon.
Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:
The primary factors that have impacted this rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks.
The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels and increase in net income. However, as a counter to these strengths, TheStreet Ratings finds that the company's return on equity has been disappointing.
You can view the full analysis from the report here: PFE